首页> 外文期刊>Biochemistry >Structural analysis of NSAID biding by prostaglandin H_2 synthase:time-dependent and time-independent inhibitors elicit identical enzyme conformations
【24h】

Structural analysis of NSAID biding by prostaglandin H_2 synthase:time-dependent and time-independent inhibitors elicit identical enzyme conformations

机译:前列腺素H_2合酶对NSAID招标的结构分析:时间依赖性和时间依赖性抑制剂引起相同的酶构象

获取原文
获取原文并翻译 | 示例
           

摘要

Nonsteroidal antiinflammatory drugs (NSAJDs) block prostanoid biosynthesis by inhibiting prostaglandin H2 synthase (EC 1.14.99.1). NSAIDs are either rapidly reversible competitive inhibitors or slow tight-binding inhibitors of this enzyme. These different modes of inhibition correlate with clinically important differences in isoform selectivity. Hypotheses have been advanced to explain the different inhibition kinetics, but no structural data have been available to test them. We present here crystal structures of prostaglandin H2 synthase- 1 in complex with the inhibitors ibuprofen, methyl flurbiprofen, flurbiprofen, and alclofenac at resolutions ranging from 2.6 to 2.75 A. These structures allow direct comparison of enzyme complexes with reversible competitive inhibitors (ibuprofen and methyl flurbiprofen) and slow tight-binding inhibitors (alclofenac and flurbiprofen). The four inhibitors bind to the same site and adopt similar conformations. In all four complexes, the enzyme structure is essentially unchanged, exhibiting only minimal differences in the inhibitor binding site. These results argue strongly against hypotheses that explain the difference between slow tight-binding and fast reversible competitive inhibition by invoking global conformational differences or different inhibitor binding sites. Instead, they suggest that the different apparent modes of NSAID binding may result from differences in the speed and efficiency with which inhibitors can perturb the hydrogen bonding network around Arg- 120 and Tyr-355.
机译:非甾体类抗炎药(NSAJDs)通过抑制前列腺素H2合酶(EC 1.14.99.1)来阻断前列腺素的生物合成。 NSAID是该酶的快速可逆竞争性抑制剂或慢速紧密结合抑制剂。这些不同的抑制方式与同工型选择性的临床重要差异相关。假设已被提出来解释不同的抑制动力学,但尚无结构数据可用于测试它们。我们在此介绍前列腺素H2合酶-1与抑制剂布洛芬,甲基氟比洛芬,氟比洛芬和alclofenac的复合物的晶体结构,分辨率范围为2.6至2.75A。这些结构可以直接比较酶制剂与可逆竞争性抑制剂(布洛芬和甲基氟比洛芬)和慢速紧结合抑制剂(alclofenac和氟比洛芬)。四种抑制剂结合到相同的位点并采用相似的构象。在所有四个复合物中,酶的结构基本不变,在抑制剂结合位点上仅表现出最小的差异。这些结果强烈反对假说,这些假说通过调用整体构象差异或不同的抑制剂结合位点来解释慢速紧密结合和快速可逆竞争抑制之间的差异。相反,他们认为,NSAID结合的不同表观模式可能是由于抑制剂干扰Arg-120和Tyr-355周围氢键网络的速度和效率不同所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号